[Form 4] Akero Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Akero Therapeutics insider transactions on 09/02/2025 show Jonathan Young, Chief Operating Officer, exercised stock options and sold an equal number of shares under a Rule 10b5-1 plan. The filing reports an exercise/acquisition of 12,500 shares at $21.10 and sales totaling 12,500 shares executed at weighted-average prices of $45.776, $47.136 and $47.58. After these transactions Mr. Young beneficially owned 197,484 shares direct and additionally has three irrevocable trusts holding 20,000 shares each, which he disclaims as beneficial ownership. The transactions were effected pursuant to a 10b5-1 trading plan dated April 29, 2025.

Positive

• Exercise of options: Acquisition of 12,500 shares via option exercise at $21.10 shows executive converting equity compensation into stock ownership.
• Use of 10b5-1 plan: Transactions were executed pursuant to a Rule 10b5-1 trading plan dated April 29, 2025, indicating trades were prearranged.
• Full disclosure: Filing provides weighted-average sale prices and offers to provide per-trade details upon request.

Negative

• Insider selling: Sales of 12,500 shares on 09/02/2025 reduce direct holdings from reported pre-transaction levels.
• Concentrated holdings in trusts: Three irrevocable trusts each hold 20,000 shares; the reporting person disclaims beneficial ownership, which may complicate assessment of insider alignment.

Insights

Securities Analyst

TL;DR: Insider exercised 12,500 options at $21.10 then sold 12,500 shares under a 10b5-1 plan, realizing proceeds well above strike.

Jonathan Young exercised a stock option to acquire 12,500 shares at a $21.10 exercise price and contemporaneously sold 12,500 shares across multiple trades on 09/02/2025 under a Rule 10b5-1 plan. The reported sale prices are materially higher than the exercise price, indicating a significant gross spread per share. This is a routine liquidity event for an executive and was prearranged under a written trading plan, reducing potential signaling of opportunistic trading. The filing discloses direct ownership of 197,484 shares after the transactions and three irrevocable trusts holding 20,000 shares each that the reporting person disclaims beneficial ownership of.

Corporate Governance Expert

TL;DR: Transactions were executed under a dated 10b5-1 plan and include option exercise plus matching disposals, consistent with pre-planned insider liquidity.

The report explicitly states the trades were effected pursuant to a Rule 10b5-1 trading plan dated April 29, 2025, which provides the insider an affirmative defense under Rule 10b5-1(c). The filing also discloses shares held in irrevocable trusts for beneficiaries and includes a formal disclaimer of beneficial ownership for those trust holdings. From a governance perspective, disclosure appears complete and includes weighted-average sale-price ranges and an offer to provide per-trade details on request, aligning with good disclosure practices for insider transactions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Young Jonathan

(Last) (First) (Middle)

C/O AKERO THERAPEUTICS, INC.

601 GATEWAY BOULEVARD, SUITE 350

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Akero Therapeutics, Inc. [ AKRO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/02/2025		M(1)		12,500	A	$21.1	209,984	D
Common Stock	09/02/2025		S(1)		9,700	D	$45.776(3)	200,284	D
Common Stock	09/02/2025		S(1)		2,739	D	$47.136(4)	197,545	D
Common Stock	09/02/2025		S(1)		61	D	$47.58	197,484	D
Common Stock								20,000	I	By EA Irrevocable Trust(2)
Common Stock								20,000	I	By CM Irrevocable Trust(2)
Common Stock								20,000	I	By JL Irrevocable Trust(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$21.1	09/02/2025		M(1)			12,500	(5)	12/07/2031	Common Stock	82,482	$0	57,482	D

Explanation of Responses:

1. The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated April 29, 2025, previously adopted by the Reporting Person.

2. These shares are held in irrevocable trusts for the benefit of the Reporting Person's children. The Reporting Person's spouse is trustee of the trusts. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

3. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $45.48 to $46.27, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote.

4. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $46.54 to $47.54, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote.

5. This option shall vest and become exercisable in 48 equal monthly installments, commencing on December 8, 2021

	/s/ Jonathan Young	09/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did Jonathan Young report on Form 4 for AKRO?

The Form 4 reports an exercise/acquisition of 12,500 shares at $21.10 and sales totaling 12,500 shares executed on 09/02/2025.

Were the sales executed under a Rule 10b5-1 trading plan for AKRO?

Yes. The filing states the reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated April 29, 2025.

How many AKRO shares does Jonathan Young beneficially own after these transactions?

The filing shows 197,484 shares beneficially owned directly following the reported transactions.

Does Jonathan Young hold shares indirectly for family members?

Yes. The filing discloses three irrevocable trusts (EA, CM, JL) each holding 20,000 shares, and the reporting person disclaims beneficial ownership of those trust shares.

What sale prices were reported for the AKRO share disposals?

Sales were reported at weighted-average prices: $45.776, $47.136, and $47.58, with disclosed intra-range trade details available on request.